Conference item

Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Osterborg, A., Dyer, M., Mayer, J., Hess, G., Hillmen, P., Schetelig, J., Schuh, A., Smolej, L., Beck, C., Dreyfus, B., Hellman, A., Kozlowski, P., Pfreundschuh, M., Rizzi, R., Spacek, M., Chan, G., Gupta, I., Phillips, J., Lisby, S., & Wierda, W. (2012). Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

MLA Style

Osterborg, A., et al. “Ofatumumab Retreatment and Maintenance in Patients with Fludarabine-Refractory CLL.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, 2012.

Chicago Style

Osterborg, A, M Dyer, J Mayer, G Hess, P Hillmen, J Schetelig, A Schuh, et al. 2012. “Ofatumumab Retreatment and Maintenance in Patients with Fludarabine-Refractory CLL.” In JOURNAL OF CLINICAL ONCOLOGY. Vol. 30.
Share
Print

Authors

+ Osterborg, A More by this author

Role:: Author

+ Dyer, M More by this author

Role:: Author

+ Mayer, J More by this author

Role:: Author

+ Hess, G More by this author

Role:: Author

+ Hillmen, P More by this author

Role:: Author

More authors...

Host title:: JOURNAL OF CLINICAL ONCOLOGY
Volume:: 30
Issue:: 15
Publication date:: 2012-05-20
ISSN:: 0732-183X

Pubs id:: pubs:406277
UUID:: uuid:63a8f355-1d2b-49d5-903b-9c44abfb0394
Local pid:: pubs:406277
Source identifiers:: 406277
Deposit date:: 2013-11-16

Terms of use

Copyright date:: 2012

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP